Abstract
Genetics is an import risk factor for amyotrophic lateral sclerosis (ALS), a devastating neurodegenerative disease affecting motor neurons. Recent findings demonstrate that, in addition to specific genetic mutations, structural variants caused by genetic instability can also play a causative role in ALS. Genomic instability can lead to deletions, duplications, insertions, inversions, and translocations in the genome, and these changes can sometimes lead to fusion of distinct genes into a single transcript. While such gene fusion events have been studied extensively in cancer, they have not been thoroughly investigated in ALS. We leveraged bulk RNA-Seq data from human post-mortem samples to determine whether fusion events occur in ALS. We report for the first time the presence of gene fusion events in several brain regions as well as in spinal cord samples in ALS. Although most gene fusions were intra-chromosomal events between neighboring genes and present in both ALS and control samples, there was a significant increase in the number of unique gene fusion in ALS compared to controls. Lastly, we have identified specific gene fusions with a significant burden in ALS, that were absent from both control samples and known cancer gene fusion databases. Collectively, our findings reveal an enrichment of gene fusion in ALS and suggest that these events may be an additional genetic cause linked to ALS pathogenesis.
Competing Interest Statement
J.D.B. has received personal fees from Biogen, Clene Nanomedicine and MT Pharma Holdings of America, and grant support from Alexion, Biogen, MT Pharma of America, Anelixis Therapeutics, Brainstorm Cell Therapeutics, Genentech, nQ Medical, NINDS, Muscular Dystrophy Association, ALS One, Amylyx Therapeutics, ALS Association, and ALS Finding a Cure. M.E.C. acts as consultant for Aclipse, Mt Pharma, Immunity Pharma Ltd., Orion, Anelixis, Cytokinetics, Biohaven, Wave, Takeda, Avexis, Revelasio, Pontifax, Biogen, Denali, Helixsmith, Sunovian, Disarm, ALS Pharma, RRD, Transposon, and Quralis, and as DSBM Chair for Lilly. K.V. is an advisor to Novathena. E.F. acts as a consultant for MT Pharma. G.S.V. is a consultant for MarvelBiome. None of these had any influence over the current paper.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Partners Healthcare IRB.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵^ See supplemental material for more details
We have reanalyzed the data sets from Target ALS and the NYGC ALS Consortium and updated results and figures accordingly.
Data Availability
All data produced in the present study are available upon reasonable request to the corresponding author.
